Lilly, Ascidian Launch Up-to-$1.9B RNA Exon Editor Collaboration Targeting Inherited Kidney Diseases
Eli Lilly has expanded its genetic medicines pipeline and capabilities, agreeing to partner with Ascidian Therapeutics to develop RNA exon editors intended to treat inherited kidney diseases, through ...
Discover how Merchant Category Codes (MCCs) classify purchases for card rewards, tax reporting, and fees. Learn how they ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results